US FDA upgrades Jubilant's troubled Washington plant to VAI

By Dan Stanton contact

- Last updated on GMT

The Spokane, Washington plant has been upgraded to Voluntary Action Indicated (VAI)
The Spokane, Washington plant has been upgraded to Voluntary Action Indicated (VAI)

Related tags: Food and drug administration

A Jubilant HollisterStier sterile manufacturing facility hit with a warning letter in 2013 has been upgraded following inspections by the US FDA last year.

In November 2013, the US Food and Drug Administration issued a warning letter​ to the site in Spokane, Washington after an inspection found the drug and ingredient maker had committed a number of cGMP violations including the “failure to assure an adequate system for cleaning and disinfecting aseptic processing areas and equipment.”

But in a letter filed Friday with the Bombay Stock Exchange, the contract manufacturing organisation’s (CMO) parent company Jubilant Life Sciences said the regulatory agency has upgraded the plant from the status of Official Action Indicated (OAI) to Voluntary Action Indicated (VAI).

“Jubilant remains committed to continuous improvements to maintain compliance at all its pharmaceutical manufacturing facilities across the globe,”​ said Jubilant’s Chairman Shyam Bhartia and Co-Chairman Hari  Bhartia in a joint statement.

“We consider this development as another step towards building a reliable and sustainable pharmaceutical business.”

The Spokane site consists of two manufacturing complexes offering customers aseptic filling and lyophilisation, producing batch sizes from 20 to 3,000L.

Other violations cited in the 2013 letter were the presence of unknown impurities in a finished product which led to a voluntary recall, and issues with the firm’s lack of provisions “for adequate impact evaluation of significant maintenance shutdowns.”

The firm also has a sterile filling and lyophilisation site in Montreal, Canada which was hit with a warning letter​ in February 2013 after FDA inspectors observed water running on the floor between the equipment wash room and the corridor leading to the vial filling area. A close-out letter​ was issued in September 2014.

Related news

Show more

Related products

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars